MA32878B1 - Virus syncytial respiratoire vivant attenue - Google Patents

Virus syncytial respiratoire vivant attenue

Info

Publication number
MA32878B1
MA32878B1 MA33913A MA33913A MA32878B1 MA 32878 B1 MA32878 B1 MA 32878B1 MA 33913 A MA33913 A MA 33913A MA 33913 A MA33913 A MA 33913A MA 32878 B1 MA32878 B1 MA 32878B1
Authority
MA
Morocco
Prior art keywords
vsr
respiratory syncytial
syncytial virus
virus attenuated
attenuated
Prior art date
Application number
MA33913A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32878B1 publication Critical patent/MA32878B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA33913A 2008-11-05 2011-06-03 Virus syncytial respiratoire vivant attenue MA32878B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05
PCT/US2009/063024 WO2010053883A1 (en) 2008-11-05 2009-11-03 Live, attentuated respiratory syncytial virus

Publications (1)

Publication Number Publication Date
MA32878B1 true MA32878B1 (fr) 2011-12-01

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33913A MA32878B1 (fr) 2008-11-05 2011-06-03 Virus syncytial respiratoire vivant attenue

Country Status (19)

Country Link
US (1) US9011876B2 (OSRAM)
EP (1) EP2346990B1 (OSRAM)
JP (2) JP5016731B2 (OSRAM)
KR (1) KR20110063863A (OSRAM)
CN (1) CN102272295A (OSRAM)
AU (1) AU2009311287C1 (OSRAM)
BR (1) BRPI0921424A2 (OSRAM)
CA (1) CA2742086A1 (OSRAM)
CL (1) CL2011000999A1 (OSRAM)
CO (1) CO6362047A2 (OSRAM)
EC (1) ECSP11011033A (OSRAM)
IL (1) IL212437A0 (OSRAM)
MA (1) MA32878B1 (OSRAM)
MX (1) MX2011004719A (OSRAM)
PE (1) PE20110394A1 (OSRAM)
RU (1) RU2011122615A (OSRAM)
TN (1) TN2011000182A1 (OSRAM)
WO (1) WO2010053883A1 (OSRAM)
ZA (1) ZA201103259B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346990B1 (en) * 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
WO2013026054A2 (en) * 2011-08-18 2013-02-21 Axella Solutions, Llc Production of infectious rna viruses in yeast
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
AU2014214763B2 (en) * 2013-02-08 2020-02-27 The Research Foundation For The State University Of New York Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP3798310A1 (en) * 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
US10429129B2 (en) 2013-10-16 2019-10-01 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2017030997A1 (en) * 2015-08-14 2017-02-23 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered ns1 protein function and related materials and methods
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
WO2018057950A1 (en) 2016-09-23 2018-03-29 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
AU2018331467A1 (en) * 2017-09-15 2020-04-30 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (RSV) infections
WO2025106787A1 (en) * 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Trehalose vaccine formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250883A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
EP1064358A2 (en) 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
EP1287152B1 (en) 1999-07-09 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Human-bovine chimeric respiratory syncytial virus vaccines
US20050176130A1 (en) 2002-09-27 2005-08-11 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
JP4783726B2 (ja) * 2003-03-28 2011-09-28 メディミューン，エルエルシー 呼吸器合胞体ウイルスサブグループｂ株９３２０に関連する組成物および方法
CN101646768A (zh) * 2007-02-07 2010-02-10 生物载体株式会社 减毒负链rna病毒
EP2346990B1 (en) * 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus

Also Published As

Publication number Publication date
MX2011004719A (es) 2011-05-31
JP5743794B2 (ja) 2015-07-01
CO6362047A2 (es) 2012-01-20
JP2011250798A (ja) 2011-12-15
BRPI0921424A2 (pt) 2016-01-05
CN102272295A (zh) 2011-12-07
JP5016731B2 (ja) 2012-09-05
ZA201103259B (en) 2012-01-25
CL2011000999A1 (es) 2012-07-20
US20110212130A1 (en) 2011-09-01
CA2742086A1 (en) 2010-05-14
IL212437A0 (en) 2011-06-30
TN2011000182A1 (en) 2012-12-17
EP2346990A1 (en) 2011-07-27
JP2012507302A (ja) 2012-03-29
AU2009311287C1 (en) 2015-02-19
EP2346990B1 (en) 2016-01-06
RU2011122615A (ru) 2012-12-20
AU2009311287A1 (en) 2010-05-14
KR20110063863A (ko) 2011-06-14
PE20110394A1 (es) 2011-06-22
WO2010053883A1 (en) 2010-05-14
AU2009311287B2 (en) 2013-02-07
ECSP11011033A (es) 2011-12-30
US9011876B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
MA32878B1 (fr) Virus syncytial respiratoire vivant attenue
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
CY1118090T1 (el) Αντιγονα ανασυνδυασμενου rsv
EA201070066A1 (ru) Вакцины против гриппа с низким содержанием добавок
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
MA31428B1 (fr) Vaccin
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
CY1113824T1 (el) Ενδορινικες συνθεσεις
CR11307A (es) Vacunas
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
WO2008010099A3 (en) Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
WO2009005040A1 (ja) 緑膿菌の外膜タンパク質pa4710
WO2010101750A3 (en) Attenuated salmonella enterica serovar paratyphi a and uses thereof
ATE491720T1 (de) Impfstoff gegen pasteurella multocida
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
ATE535253T1 (de) Impfstoff gegen mycoplasma prrsv
WO2007053489A3 (en) Attenuated salmonella enterica serovar paratyphi a and uses thereof
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
WO2009076542A3 (en) Vaccine directed against adenovirus serotype 14